



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Walker, IS;Dini, S;Aitken, EH;Damelang, T;Hasang, W;Alemu, A;Jensen, ATR;Rambhatla, JS;Opi, DH;Duffy, MF;Takashima, E;Harawa, V;Tsuboi, T;Simpson, JA;Mandala, W;Taylor, TE;Seydel, KB;Chung, AW;Rogerson, SJ

Title:

A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children

Date:

2024-12-01

Citation:

Walker, I. S., Dini, S., Aitken, E. H., Damelang, T., Hasang, W., Alemu, A., Jensen, A. T. R., Rambhatla, J. S., Opi, D. H., Duffy, M. F., Takashima, E., Harawa, V., Tsuboi, T., Simpson, J. A., Mandala, W., Taylor, T. E., Seydel, K. B., Chung, A. W. & Rogerson, S. J. (2024). A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children. *BMC Medicine*, 22 (1), <https://doi.org/10.1186/s12916-024-03604-8>.

Persistent Link:

<https://hdl.handle.net/11343/358694>

License:

[CC BY](#)

RESEARCH ARTICLE

Open Access



A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children

Isobel S. Walker¹, Saber Dini², Elizabeth H. Aitken^{3,4}, Timon Damelang⁴, Wina Hasang³, Agersew Alemu³, Anja T. R. Jensen⁵, Janavi S. Rambhatla^{1,4}, D. Herbert Opi^{1,6,7}, Michael F. Duffy^{1,4}, Eizo Takashima⁸, Visopo Harawa⁹, Takafumi Tsuboi¹⁰, Julie A. Simpson², Wilson Mandala¹¹, Terrie E. Taylor^{12,13}, Karl B. Seydel^{12,13}, Amy W. Chung⁴ and Stephen J. Rogerson^{1,3*}

Abstract

Background *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) proteins are expressed on the surface of infected erythrocytes, mediating parasite sequestration in the vasculature. PfEMP1 is a major target of protective antibodies, but the features of the antibody response are poorly defined.

Methods In Malawian children with cerebral or uncomplicated malaria, we characterized the antibody response to 39 recombinant PfEMP1 Duffy binding like (DBL) domains or cysteine-rich interdomain regions (CIDRs) in detail, including measures of antibody classes, subclasses, and engagement with Fcγ receptors and complement. Using elastic net regularized logistic regression, we identified a combination of seven antibody targets and Fc features that best distinguished between children with cerebral and uncomplicated malaria. To confirm the role of the selected targets and Fc features, we measured antibody-dependent neutrophil and THP-1 cell phagocytosis of intercellular adhesion molecule-1 (ICAM-1) and endothelial protein C (EPCR) co-binding infected erythrocytes.

Results The selected features distinguished between children with cerebral and uncomplicated malaria with 87% accuracy (median, 80–96% interquartile range) and included antibody to well-characterized DBLβ3 domains and a less well-characterized CIDRy12 domain. The abilities of antibodies to engage C1q and FcγRIIIb, rather than levels of IgG, correlated with protection. In line with a role of FcγRIIIb binding antibodies to DBLβ3 domains, antibody-dependent neutrophil phagocytosis of ICAM-1 and EPCR co-binding IE was higher in uncomplicated malaria (15% median, 8–38% interquartile range) compared to cerebral malaria (7%, 30–15%, $p < 0.001$).

Conclusions Antibodies associated with protection from cerebral malaria target a subset of PfEMP1 domains. The Fc features of protective antibody response include engagement of FcγRIIIb and C1q, and ability to induce antibody-dependent neutrophil phagocytosis of infected erythrocytes. Identifying the targets and Fc features of protective immunity could facilitate the development of PfEMP1-based therapeutics for cerebral malaria.

Keywords *Plasmodium falciparum*, Malawi, Antibody, Immunity, Africa

*Correspondence:

Stephen J. Rogerson
sroger@unimelb.edu.au

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Background

There are more than 200 million cases of malaria annually that result in over half a million deaths, predominantly of children under 5 years of age [1]. Cerebral malaria is a severe and lethal manifestation of *Plasmodium falciparum* malaria that is characterized by impaired consciousness and predominantly occurs in children or adults who lack protective immunity. The pathogenesis of cerebral malaria is complex and only partially understood; however, a central component is the adhesion of parasite-infected erythrocytes (IE) to blood vessel endothelial cells in the brain, resulting in sequestration of IE in the cerebral microvasculature [2]. In the majority of cases, malaria illness is uncomplicated, with fever and non-specific symptoms including headache, myalgia, and chills, and children do not progress to cerebral malaria.

Adhesion of IE to endothelial cells is mediated by *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) variant surface antigens expressed on the IE surface. PfEMP1 are encoded by *var* genes, of which there are ~60 variants per parasite genome, with one variant expressed at a time. The majority of *var* genes can be classified as group A, B, or C based on their upstream promoter sequence (UPS A, B, or C) and chromosomal location, and encode for PfEMP1s with a combination of two to ten Duffy binding like (DBL) domains and cysteine-rich interdomain regions (CIDRs), some of which are frequently found in tandem arrangements, known as domain cassettes (DCs) [3]. Groups B/A and C/B are intermediates of two groups (A and B or C and B), and group E consists of a unique pregnancy specific *var* gene, *var2csa*. DBL and CIDR domains are further classified into multiple types (DBL α , β , γ , δ , ϵ , ζ and χ , and CIDR α , β and γ) and subtypes (denoted by numbers, e.g., CIDR α 1.1) [3]. Representative PfEMP1 structures are illustrated in Additional file 1: Fig. S1. Despite the enormous diversity in *var* genes, previous studies have identified PfEMP1 domains that are more frequently expressed in different clinical manifestations of malaria, and some of these PfEMP1 domains are known to bind to particular endothelial cell receptors. Generally, group A *var* genes are associated with severe malaria, whereas group B and C *var* genes are associated with uncomplicated malaria. PfEMP1 with CIDR α 1 domains that bind to endothelial protein C receptor (EPCR), including those within DC8, have been associated with severe and cerebral malaria [4, 5]. CIDR α 1 domains are sometimes found adjacent to a DBL β domain that binds to intercellular adhesion molecule 1 (ICAM-1), including in DC4 and DC13, enabling dual receptor binding of IEs to brain endothelial cells [6]. Dual binding PfEMP1 can be predicted by the presence of a short sequence of amino acids in group A and some group B/A DBL β domains, referred

to as DBL β _{motif} and have been associated with cerebral malaria [7, 8].

PfEMP1 is the main target of antibodies on the surface of the IE and antibodies targeting PfEMP1 or recombinant PfEMP1 domains have been associated with protection from severe malaria and uncomplicated malaria in multiple studies [9–11], including protection from uncomplicated malaria associated with antibodies to a DBL β domain [12], to “group 2” DBL α domains, and antibody to a CIDR γ 3 domain [13, 14]. However, there does not appear to be a single antigen variant that is associated with cerebral malaria in all cases, and given the high diversity of PfEMP1, it is likely that individuals would have to acquire antibodies to a combination of PfEMP1 target antigens to be protected. Previous studies have shown that antibodies targeting PfEMP1 have diverse functions, including inhibition of adhesion to endothelial cells, and promoting phagocytosis by monocytes [15] and killing of IEs by neutrophils [16], and by natural killer cell cytotoxicity [17]. However, due to the high diversity of PfEMP1, most studies have focused on a small number of domains or parasite lines and have employed a small number of functional immunoassays. Systems serology involves characterizing multiple antibody Fab targets and Fc features, followed by machine learning to identify the most relevant antibody responses [18]. We have recently used this approach to identify antibody responses that best correlate with protection from placental malaria [19].

This study aimed to characterize the antibody responses at the time of hospital presentation in Malawian children with cerebral and uncomplicated malaria and to identify a combination of antibody features that could differentiate between the two groups. We measured 11 antibody Fc features targeting 39 PfEMP1 domains that have previously been associated with severe or uncomplicated malaria [20, 21] and used machine learning to select a combination of antibody targets and Fc features that could best discriminate between cerebral and uncomplicated malaria. These results provide important new insights into the development of protective antibody immunity against cerebral malaria.

Methods

Clinical samples

Study participants were Malawian children presenting with cerebral or uncomplicated malaria to Queen Elizabeth Central Hospital, Blantyre, Malawi, over three malaria seasons (2015–2017) [22]. Malaria was diagnosed by light microscopy or rapid diagnostic test accompanied by fever >37.5 °C. Participants were classified as having cerebral malaria based on a Blantyre coma score (BCS) of ≤ 2 , or as having uncomplicated malaria based on

normal consciousness and a BCS of 5 [23]. Participants were included if they were aged between 6 months and 12 years and were excluded if they tested positive to HIV, had recent history of non-malaria illness, or appeared severely malnourished. Venous blood samples were collected at enrollment. Plasma was separated and stored at -80°C . To minimize differences in prior exposure to malaria, we matched individuals with cerebral and uncomplicated malaria based on village of residency and rural or urban environment. Five samples were further removed due to inadequate volumes to complete all assays. Plasma from 10 adults from a non-malaria endemic area (Melbourne, Australia) were included in each assay as negative controls.

Recombinant proteins

The study included recombinant proteins previously associated with severe, cerebral, or uncomplicated malaria (see Additional file 1: Table 1). This included 28 PfEMP1 domains derived from *var* sequences that were upregulated in severe or uncomplicated malaria in Indonesian adults and children (coded as SM or UM, respectively) [10] and 11 PfEMP1 DBL β domains associated with ICAM-1 or non-ICAM-1 binding PfEMP1 [21, 24, 25]. We included four merozoite antigens, merozoite surface protein-2 (MSP2), MSP3, erythrocyte binding antigen-175 (EBA175-RIII-B), and apical membrane antigen-1 (AMA1), and a sporozoite antigen, circumsporozoite protein (CSP), as markers of prior exposure. Tetanus toxoid antigen was used as a positive control and an antigen-free bead region was used as a negative control (see Additional file 1: Table 2).

Multiplex immunoassay

A multiplex immunoassay was used to assess antibody reactivity and antigen-specific antibody features to the selected recombinant PfEMP1 domain antigens, as previously described in detail [26]. Recombinant proteins were coupled to Bio-Plex magnetic carboxylated beads (Bio-Rad, Hercules, CA, USA) as per the manufacturer's instructions. For each assay, protein coupled beads were combined to a final concentration of 20 beads/ μL per bead region in 1% bovine serum albumin in phosphate buffered saline (BSA/PBS). Combined beads were incubated in a 96-well plate (Corning, Corning, NY, USA) with participant plasma, diluted 1:50 in PBS, overnight at 4°C on a plate shaker. Beads were washed with 1% BSA/PBS and incubated with detector antibody. We compared IgG responses to antigens probed in single format to multiplex array format, to confirm there was minimal antibody competition or interaction between antigens (see Additional file 1: Fig. S2). To detect IgG, IgG1, IgG2, IgG3, and IgG4, beads were incubated with

phycoerythrin (PE) conjugated fluorescent anti-human IgG, IgG1, IgG2, IgG3, or IgG4 antibody (1.3 $\mu\text{g}/\text{mL}$ in 1% BSA/PBS, Southern Biotech, Birmingham, AL, USA). To detect IgM, beads were incubated with a primary biotinylated anti-human IgM antibody (1.3 $\mu\text{g}/\text{mL}$ in 1% BSA/PBS, MabTech, Sweden), for 2 h, followed by streptavidin-PE conjugated secondary detector (1.3 $\mu\text{g}/\text{mL}$ in 1% BSA/PBS, Thermo Fisher Scientific, Waltham, MA, USA), for 1 h. To detect Fc receptor binding to antibodies, biotinylated recombinant human Fc γ RIIb and Fc γ RIIIb monomers (ACROBiosystems, Newark, DE, USA) were pre-conjugated to streptavidin-PE at a ratio of 4:1 mol to form fluorescent tetramers. Fc γ RIIIa-His¹³¹ and Fc γ RIIIa-Val¹⁵⁸ were available as biotinylated, soluble homodimers [27]. Tetramers or dimers were diluted to 1.3 $\mu\text{g}/\text{mL}$ in 1% BSA/PBS and incubated with beads, for 2 h. To detect C1q binding to antibody, recombinant C1q (MP Biochemicals, Irvine, CA, USA) was biotinylated using the EZ-LinkTM Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions, using a 1:5 mol ratio of C1q to biotin. Biotinylated recombinant C1q was conjugated to streptavidin-PE at a 4:1 mol ratio to form fluorescent tetramers, which were diluted to 15.92 $\mu\text{g}/\text{mL}$ in 1% BSA/PBS and incubated with beads, for 2 h. Median fluorescent intensities (MFI) from a minimum of 40 beads per region were acquired on a Luminex instrument (Bio-Plex[®] MAGPIXTM or Flexmap3D). Experiments were performed once with 37% of samples duplicated in each plate.

Infected erythrocyte selection

P. falciparum IE were cultured in type O+ human erythrocytes from healthy donors, as previously described [28]. 3D7 and IT4 IE were selected for expression of PfEMP1 that are predicted to bind to ICAM-1 (3D7VAR04 and IT4VAR13), as described in Joergensen et al. [29], using antibody raised against the ICAM-1 binding DBL β domain of 3D7VAR04 (Pfd1235w) [30] and IT4VAR13 PfEMP1 [6]. 3D7VAR04 were further enriched by fluorescence activated cell sorting. Isolated trophozoite stage IE were incubated with 0.16 mg/mL monoclonal mouse anti-human VAR04 DBL β 3 [30] and 4 $\mu\text{g}/\text{mL}$ anti-IgG Fc-AF647 (Invitrogen) secondary antibody. IE were gated by forward and side scatter using unstained IE and AF647 labeled IE were sorted. The percentage of IE in culture expressing the selected PfEMP1 was monitored by flow cytometry (CytoFLEX, Beckman Coulter). IE were stained with 25 $\mu\text{g}/\text{mL}$ dihydroethidium bromide (DHE, Sigma) and 0.16 mg/mL mouse anti-human VAR04 DBL β or rat anti-serum against VAR13 DBL β 3 [6], and 4 $\mu\text{g}/\text{mL}$ anti-IgG Fc-AF647 secondary antibody.

Gating for AF647 positive events was set using stain-free controls. The estimated percentage of parasites expressing VAR04 (Pfd1235w) prior to experiments ranged from 44 to 55% and the estimated expression of VAR13 ranged from 36 to 52%.

Antibody-dependent neutrophil and THP-1 cell phagocytosis assay

Antibody-dependent THP-1 cell phagocytosis of 3D7VAR04 and IT4VAR13 IE was performed as described in Ataide et al. [31] and in Kassa et al. [32]. The THP-1 monocyte-like cell line, which expresses FcγRI and FcγRIIa/b but lacks FcγRIIIa/b, has been used to study antibody-dependent cellular phagocytosis for some time [33]. Antibody-dependent neutrophil phagocytosis of 3D7VAR04 and IT4VAR13 IE was performed as described in Aitken et al. [19]. Neutrophils were isolated from fresh venous blood from two healthy non-immune volunteers using the EasySep Direct Human Neutrophil Isolation Kit (STEMCELL Technologies, Tullamarine, Australia) as described [19]. IE were labeled with dihydroethidium bromide and the “percentage phagocytosis” was defined as the frequency of THP-1 or neutrophil cell events that were positive for DHE, relative to a rabbit anti-human red blood cell positive control serum. For neutrophils, the average percentage phagocytosis from the two experiments was used. Wilcoxon rank sum test was used to compare median antibody responses between groups. Each experiment was performed once with all samples in duplicate.

Statistical analysis for identification of key antibody features

Prior to analysis, we subtracted the serum-free control and antigen-free control region MFI. We normalized between plates by fitting a linear or non-linear equation to 36 duplicated samples from each plate. Negative fluorescence intensities were converted to a value of 1. Antigen specific antibody features were labeled with the following format: “Fc feature.protein identifier_domain description” (see Additional file 1: Table 1). Four variables were eliminated as all values were below background (FcγRIIIb.SM14_DBLy3, C1q.SM5_DBLβ3, FcγRIIb.SM26_CIDRy12, IgG2.SM5_DBLβ3) and two antigens were not included for all Fc detectors due to low protein availability (SM27_DBLδ7 and UM1_DBLα0.13, only probed for IgG, IgG1, IgG2, IgG3, and IgG4). Merozoite and sporozoite antigens were not included for all Fc detectors due to low protein availability (AMA1 only probed for IgG and IgG1, MSP3 not probed for IgG1, EBA175-RIII-B not probed for IgG1, IgG2, IgG3, and IgG4, and CSP not probed for Fcγ receptors).

To compare the mean difference in antibody levels for each antigen between patients with cerebral malaria and uncomplicated malaria, data were $\log(x+1)$ transformed (to adjust for right skewedness) and the means were compared by a Welch’s *t*-test. A *p* value < 0.05 and a $\log_2(\text{fold change}) > 1$ (i.e., > twofold change in geometric means of antibody levels) were considered significant differences and there was no adjustment for multiple comparisons. To evaluate the influence of age, we divided the population around the median age of 49 months for some analyses. To group responses to multiple proteins, the geometric mean of responses was calculated for each individual. To select a combination of features that best distinguish between cerebral and uncomplicated malaria, we performed multivariable logistic regression coupled with machine learning, as previously described with minor changes [19]. Merozoite antigens were excluded from the multivariable analysis. Data were $\log(x+1)$ transformed, mean centered, and scaled to one standard deviation. Missing values were imputed as the median of five imputed data sets using multivariate imputations by chained equations [34] with predictive mean matching. Elastic net regularized logistic regression (ENLR) [35] was used to identify features that best distinguish between cerebral and uncomplicated malaria. We performed 5000 repeats of ENLR with the α tuning parameter set to 0.5. For each repeat, the data were randomly split into 10 folds, with nine folds used to fit the model across a range of lambda values and one fold to assess the area under the receiver operator curve (AUROC, tenfold cross validation). The features that appeared in the model with the greatest AUROC and the odds ratio (OR) for each feature were recorded. Features were ranked based on the frequency with which they appeared in the model with the greatest AUROC across 50,000 models (5000 repeats with tenfold cross validation). Alpha tuning parameters from 0.25 or 1 were also assessed. To determine a minimum set of variables that could be linearly combined by partial least squares regression (PLSR) to explain the variation in cerebral and uncomplicated malaria, we added one feature at a time to a PLSR model, in order of frequency that they appeared in the ENLR. We performed 500 repeats of tenfold cross validation to estimate the AUROC after the addition of each feature and selected the top features whose addition resulted in a significant increase in the AUROC. We assessed the performance of the linear combination of selected features to classify samples as cerebral and uncomplicated malaria by fitting the selected features to a PLSR model and computing the AUROC (as above, the estimation was from 500 repeats of tenfold cross validation). The PLSR performance was also assessed with randomly shuffled outcome variables and random feature selection.

Results

Characteristics of the Malawian children

The final cohort included 51 children with cerebral malaria (median age of 51 months) and 46 with uncomplicated malaria (median age of 48 months). Children with cerebral malaria had a Blantyre coma score of 0–2 and 42 (82%) were retinopathy positive [36] (Table 1).

Univariate analysis of differences in antibody responses in cerebral and uncomplicated malaria

We measured antibody responses to 39 recombinant PfEMP1 domains that have been associated with severe malaria, cerebral malaria, or uncomplicated malaria. We also included 5 recombinant merozoite and sporozoite antigens, an antigen-free negative control, and tetanus toxoid as a positive control. We measured 11 antigen-specific antibody Fc features: IgG, IgM, IgG subclasses IgG1, IgG2, IgG3, and IgG4, and antibody Fc binding to recombinant FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIIb, and C1q. The final analysis included a total of 451 features, 413 of which were related to PfEMP1 antigens and 38 of which were related to merozoite or sporozoite antigens.

Half of the recombinant PfEMP1 proteins (19 out of 39) were recognized by IgG antibodies in at least 25% of children with cerebral and uncomplicated malaria (see Additional file 1: Fig. S3). We first used a volcano

plot to display univariate analyses comparing antibody responses for each PfEMP1 protein and antibody Fc features between children with cerebral and uncomplicated malaria. IgG to one PfEMP1 domain, SM9_DBLδ1, was significantly elevated by greater than twofold in cerebral malaria compared to uncomplicated malaria (Fig. 1A). IgG, IgG1, and FcγRIIIb responses to the merozoite antigen, MSP2, were significantly higher in cerebral than uncomplicated malaria and there were no other significant differences for other non-PfEMP1 antigens. Antibody features that were significantly elevated in uncomplicated malaria were IgG2 targeting SM4_DBLβ, IgG4 targeting SM5_DBLβ, IgG4 targeting Dd2VAR32_DBLβ1, FcγRIIa binding antibodies targeting SM5_DBLβ and SM3_DBLβ12, FcγRIIIb binding antibodies targeting PFD1235w_DBLβ, SM26_CIDRγ12, and SM5_DBLβ, and C1q fixing antibodies targeting IT4VAR13_DBLβ and PF11_0521_DBLβ (Fig. 1A).

Given that age is an important determinant of PfEMP1 antibody [37], we divided the children into those older or younger than the median age of 49 months. Amongst children under 49 months old, IgG targeting SM9_DBLδ1 remained significantly greater in cerebral malaria, and C1q response to IT4VAR13_DBLβ3 remained significantly greater in uncomplicated malaria. C1q response to SM3_DBLβ12 was also significantly

Table 1 Summary of study population categorized by disease severity

Characteristic	Uncomplicated malaria (n = 46)	Cerebral malaria (n = 51)
Age, median [IQR], months	48 [29–88]	51 [28–83]
Age group, n (%)		
0–48 months	24 (52%)	25 (49%)
49+ months	22 (48%)	26 (51%)
Sex, n (%)		
Female	19 (41%)	16 (31%)
Male	27 (59%)	35 (69%)
Location, n (%)		
Urban	25 (54%)	25 (49%)
Rural	21 (46%)	26 (51%)
BCS, n (%)		
0	0 (0%)	5 (10%)
1	0 (0%)	15 (29%)
2	0 (0%)	31 (61%)
5	46 (100%)	0 (0%)
Retinopathy positive, n (%)	0	42 (82%)
Severe anemia, n (%)	0	11 (23%)
Temperature, median [IQR], degrees Celsius	38.6 [37.8–39.3]	39 [38.5–39.4]
Parasitemia, median [IQR], per mL	N/A	4599 [396–58,880]
Hemoglobin, median [IQR], g/dL	10.4 [9.0–11.7]	8.2 [7.2–9.2]

Slides from children with uncomplicated malaria were counted using '+'s. Actual parasitaemias were not available

IQR Inter-quartile range, N/A Data not available




Fig. 1 Individual antibody features to recombinant proteins compared between cerebral and uncomplicated malaria. **A** All individuals, **B** children under 49 months, **C** children 49 months and older. X-axis represents the magnitude of difference (\log_2 transformed) between the geometric mean antibody levels of the cerebral and uncomplicated malaria groups. Vertical lines at $\log_2(2)$ and $\log_2(0.50)$ indicate a twofold elevation in uncomplicated malaria or cerebral malaria, respectively. Y-axis represents $-\log_{10}$ transformed p value from Welch's t -test comparison of cerebral and uncomplicated malaria. Horizontal line indicates $\log_{10}(0.05)$ threshold of statistical significance, and there were no adjustments for multiple comparisons. DBL Duffy binding like domain, CIDR cysteine-rich interdomain region, α , β , δ , ϵ , γ , ζ

greater in uncomplicated malaria (Fig. 1B). In children over 49 months, IgG1 to SM1_CIDR α 2.4 was significantly greater in cerebral malaria compared to uncomplicated malaria, although it was not significantly elevated in all children combined. Features that were significantly higher in uncomplicated malaria were IgG4 to

Dd2VAR32_DBL β 1 and SM5_DBL β 3, Fc γ RIIIb binding antibodies targeting PFD1235w_DBL β , and Fc γ RIIa binding antibodies targeting UM8_DBL γ 9 (Fig. 1C). The last of these was not significantly increased in the whole group in Fig. 1A. Amongst children with cerebral malaria or uncomplicated malaria, there were no correlations

between age and antibody responses to features that were significantly different in cerebral and uncomplicated malaria (see Additional file 1: Figs. S4 and S5).

Due to the potential importance of DBL β domains in cerebral malaria, we grouped each individual's responses to DBL β domains based on binding phenotype (using the geometric mean): group A DBL β that bind ICAM-1 with the DBL β_{motif} ICAM-1-binding motif, group A DBL β that do not bind ICAM-1, and group B DBL β that bind ICAM-1, but do not contain DBL β_{motif} (Additional file 1, Additional file 2). IgG1 antibodies targeting group B DBL β were higher in children with cerebral malaria (Welch's *t*-test *p* value 0.032). Antibodies that engage c1q and target ICAM-1-binding group A DBL β_{motif} and group B DBL β domains were higher in children with uncomplicated malaria compared to cerebral malaria (Welch's *t*-test *p* value 0.032 and 0.024, respectively) whereas antibodies targeting group A non-ICAM-1 binding DBL β domains did not differ significantly between the two clinical groups. We also grouped responses to domains that were upregulated in severe or uncomplicated malaria in a previous study in Indonesian adults and children [10], labeled as "SM" or "UM" (Additional file 1, Additional file 2). Here, IgG1 antibodies that target UM proteins were higher in cerebral malaria compared to uncomplicated malaria (*p* value 0.004). There were no significant differences between cerebral malaria and uncomplicated malaria in grouped responses to domains associated with DC8. IgG1 antibodies to group B proteins and to all proteins grouped were higher in cerebral malaria compared to uncomplicated malaria (*p* value 0.0092 and 0.017, respectively). All individual comparisons between cerebral and uncomplicated malaria for each protein and Fc feature are included in Additional file 3.

Multivariate analysis to select the combination of features that best discriminates between cerebral malaria and uncomplicated malaria

To identify the antibody features that best differentiate between cerebral and uncomplicated malaria, we

performed repeated elastic net regularized logistic regression (ENLR) [35] with tenfold cross validation and recorded the frequency and odds ratio (OR) of features selected in each model iteration, as described in Gunn et al. and Aitken et al. [19, 38]. Area under the ROC (AUROC) was used as the metric of discrimination power. The 20 most frequently selected features included both features associated with an increased odds of cerebral malaria and of uncomplicated malaria (Fig. 2A). To select a minimum combination of features that best discriminate between cerebral and uncomplicated malaria, we added features one at a time to a PLS regression model, in order of the frequency of selection based on the effect size of the odds ratio from the ENLR (Fig. 2A) and assessed the AUROC (Fig. 2B). After the seventh variable was included in the model, the AUROC did not increase by adding further variables. The top seven most frequently selected features were C1q fixing antibodies targeting IT4VAR13_DBL β 3, IgG1 targeting UM2_DBL δ 1, IgG targeting SM9_DBL δ 1, IgG2 targeting SM4_DBL β 3, IgG4 targeting Dd2VAR32_DBL β 1, and antibodies targeting SM26_CIDR γ 12 or SM5_DBL β 3 that engage Fc γ RIIIb (Fig. 2B). The univariate analyses for these features are shown in Fig. 3A. Altering the α tuning parameter to 0.25 or 1 did not change the features that were most frequently selected (see Additional file 1: Figs. S6 and S7).

To assess the predictive power of our seven selected features, we compared their ability to correctly classify children to that of seven randomly selected features. Based on the AUROC, the seven selected features could predict clinical presentation with 87% accuracy (median, 80–96% IQR) whereas seven randomly selected features could predict clinical presentation with 50% accuracy (40–53% IQR), equivalent to chance alone (Fig. 2C). The seven selected features did not generally correlate strongly with each other or with the 20 features that frequently appeared in the ENLR model iterations (Fig. 3B). There were moderate

(See figure on next page.)

Fig. 2 Multivariate analysis to select a minimum combination of features that best distinguishes between cerebral and uncomplicated malaria. A combination of elastic net regularized logistic regression (ENLR) and partial least squares (PLS) regression was used. **A** Odds ratio of antibody features from 5000 repeats of tenfold cross validated ENLR models, in order of selection frequency (top 20 most selected variables are shown). Features with median odds ratio greater than 1 represents responses associated with increased odds of uncomplicated malaria and features with median odds ratio less than 1 are associated with increased odds of cerebral malaria. **B** Performance of PLS model after addition of features (x-axis) in order of ENLR selection frequency (left to right), as measured by AUROC from 5000 repeats of tenfold cross validated PLS regression. Black line shows AUROC for all children, red line shows the accuracy of classifying children with cerebral malaria only, and blue line the accuracy of classifying children with uncomplicated malaria only. Vertical dashed line represents point at which the addition of one or two more features does not significantly increase the AUROC which occurs at seven features (referred to as the "selected features"). **C** Performance of PLS regression models using only the seven selected features from ENLR (87% median, 80–96% IQR), compared to randomly selected combinations of seven features (50% median, 40–65% IQR). AUROC corresponds to 5000 repeats of tenfold cross validated PLS regression models. AUROC area under the receiver operating characteristic curve. Box plots show median and interquartile range (IQR) and whiskers show points within $Q1 - 1.5 \times IQR$ and $Q3 + 1.5 \times IQR$. DBL Duffy binding like domain, CIDR cysteine-rich interdomain region, a, α , b, β , d, δ , e, ϵ , g, γ , z, ζ




Fig. 2 (See legend on previous page.)

correlations between DBL δ 1 domains (IgG.UM2_DBL δ 1, IgG.SM9_DBL δ 1, IgG.SM6_DBL δ 1; Spearman correlation coefficient $R=0.39$ – 0.60), moderate to strong correlations between Fc γ R binding to antibodies targeting group A DBL β domains (Fc γ RIIa.SM5_DBL β 3, Fc γ RIIb.SM5_DBL β 3, Fc γ RIIIb.SM5_DBL β 3, Fc γ RIIIb.PFD1235w_DBL β 3, Fc γ RIIb.PFD1235w_DBL β 3, $R=0.45$ – 0.81), and a moderate correlation between IgG4 responses to group A DBL β domains (IgG4.Dd2VAR32_DBL β 1 with IgG4.SM5_DBL β 3, $R=0.57$). We performed similar correlation analyses for children with severe malaria only or uncomplicated malaria only (Additional file 1: Figs. S8 and S9).

Antibody-dependent neutrophil phagocytosis of ICAM-1 + EPCR binding IE is associated with protection from cerebral malaria

To assess the role of Fc γ RIIIb binding to antibodies targeting ICAM-1 binding DBL β domains in protection from cerebral malaria, we measured antibody-dependent neutrophil phagocytosis (ADNP) of IE selected for expression of 3D7VAR04 (Pfd1235w), which co-binds to ICAM-1 and EPCR, and IT4VAR13, which co-binds to ICAM-1 and CD36 (Fig. 4). Children with uncomplicated malaria had higher ADNP of ICAM-1 + EPCR binding IE compared to children with cerebral malaria (median (IQR), 15% (8–34%) and 7% (3–15%), respectively, Wilcoxon signed-rank test $p < 0.001$). Children with cerebral malaria had higher ADNP of ICAM-1 + CD36 binding IE than children with uncomplicated malaria (4% (2–7%) and 2% (1–3%), respectively, $p = 0.025$). We also measured antibody-dependent cellular phagocytosis (ADCP) of ICAM-1 binding IE by THP-1 cells, which lack Fc γ RIIIb. Children with cerebral malaria had higher ADCP of ICAM-1 + EPCR binding IE compared to children with uncomplicated malaria (10% (6–15%) and 6% (2–9%), respectively, $p = 0.001$) and there was no statistically significant difference in THP-1 cell phagocytosis of ICAM-1 + CD36 binding IE between children with cerebral and uncomplicated malaria (9% (1–22%) and 5% (1–15%), respectively, $p = 0.52$). ADNP and ADCP using IE expressing 3D7VAR04 and ITVAR13 did not correlate with the features of the antibody response to the DBL β 3 domain of Pfd1235w or the DBL β 3 domain of VAR13, respectively (Figs. S10 and S11).

Discussion


PfEMP1 plays a key role in the pathogenesis of cerebral malaria; however, previous studies have been unable to identify a single PfEMP1 antigen to which IgG antibodies are consistently associated with protection. In this study, we performed a detailed characterization of the targets and Fc features of antibodies to PfEMP1 antigens in Malawian children with cerebral malaria and uncomplicated malaria. In univariate analyses, responses that were better developed in uncomplicated malaria included antibodies engaging Fc γ RIIa, Fc γ RIIIb and C1q, and IgG4 and IgG2 responses, primarily targeting DBL β domains. Only responses to MSP2 and IgG to one DBL δ domain were higher in cerebral than uncomplicated malaria.

We then used a previously published statistical approach that combines logistic regression and machine learning [19, 38] as an unbiased method to select a combination of features that could best differentiate antibody responses of children with cerebral and uncomplicated malaria. We found few differences in IgG but identified a combination of seven antigen-specific antibody Fc features that could differentiate between the groups with 87% accuracy, whereas randomly selected antibody features could not predict clinical presentation. This supports the idea that specific PfEMP1 variants are involved in the pathogenesis of cerebral malaria and that specific features of the Fc domains of antibodies to these variants facilitate IE clearance and prevent the development of cerebral malaria.

Four of the seven selected antibody features were targeting DBL β domains and were associated with decreased odds of cerebral malaria. Upregulated expression of group A DBL β _{motif} that contain the ICAM-1-binding motif, predictive of dual ICAM-1 and EPCR receptor binding IEs, has been clearly linked to cerebral malaria [5–8], but the role of antibodies targeting these domains in protection from cerebral malaria is less clear. Antibodies targeting group A ICAM-1 binding DBL β domains can block cytoadhesion to human brain endothelial cells and have been associated with protection from cerebral malaria in some studies [21, 39] but not in others [40, 41]. An advantage of this study is that we were able to probe multiple examples of DBL β domains, as well as multiple antibody Fc features to identify correlates of protection.

(See figure on next page.)

Fig. 3 Antibody features associated with protection from cerebral malaria and their correlation with one another. **A** Distribution of seven selected features in children with cerebral malaria (red) and uncomplicated malaria (blue). MFI readouts were $\log(x+1)$ transformed, mean centered, and scaled to 1 standard deviation (z -score). Box plots show median and interquartile range (IQR) and whiskers show $IQR + 1.5 * IQR$. Horizontal bars represent Welch's t -test comparison with p value shown. **B** Spearman correlation of features that appeared in $> 70\%$ of ENLR model iterations, including the seven selected features, using non-transformed MFI values. DBL Duffy binding like domain, CIDR cysteine-rich interdomain region, a, b, β , δ , e, γ , z, ζ . * p value < 0.05 , ** p value < 0.01 , *** p value < 0.001



☐ cerebral malaria ☐ uncomplicated malaria




Fig. 3 (See legend on previous page.)




Fig. 4 Antibody-dependent neutrophil phagocytosis and THP-1 cell phagocytosis of ICAM-1 binding IE. **A** Neutrophil phagocytosis of 3D7VAR04 ICAM-1 + EPCR co-binding IE and **B** IT4VAR13 ICAM-1 + CD36 co-binding IE. Mean responses from two neutrophil donors shown. **C** THP-1 cell phagocytosis of 3D7VAR04 ICAM-1 + EPCR co-binding IE and **D** IT4VAR13 ICAM-1 + CD36 co-binding IE. IE were opsonized with plasma from Malawian children with cerebral or uncomplicated malaria, or healthy Melbourne donors (Melbourne control). Y-axis (% phagocytosis) represents percentage of neutrophils or THP-1 cells associated with DHE stained IE, relative to a positive control serum. Boxes represent median and interquartile range (IQR) from Q1 to Q3, and whiskers range from (Q1 - 1.5*IQR) to (Q3 + 1.5*IQR). Medians (horizontal bars) were compared by Wilcoxon rank sum test and associated *p* values are shown

The selected combination of features included a group A ICAM-1 binding domain with the DBL β _{motif} as well as two group A non-ICAM-1 binding domains that lack the motif and a group B domain that binds to ICAM-1 but lacks the motif. These responses are likely influenced

by antibody cross reactivity between DBL β domains [21] and may be influenced by variants causing the current infection, as described in Olsen et al. [24].

Other PfEMP1 targets amongst the selected combination of features included two DBL δ 1 domains and

a CIDR γ 12 domain. DBL δ 1 is one of the most diverse domains [42] and there is limited data on its functions, which may be equally diverse [43, 44]. In contrast to our study, antibodies to group B and C DBL δ 1 have previously been associated with protection from severe malaria (for UM2_DBL δ 1) [13] and reduced prospective risk of hyperparasitemia [25]. In our study, antibody responses to the DBL δ 1 domains (UM2 and SM9) were highly correlated and therefore it is difficult to discern whether the antibody response in children with cerebral malaria is driven by proteins more commonly expressed in severe malaria (SM9_DBL δ 1) or uncomplicated malaria (UM2_DBL δ 1). Similarly, little is known about the function of SM26_CIDR γ 12, other than that CIDR γ are part of the head structure of a rosetting parasite line [45]. Antibodies to SM26_CIDR γ 12 were elevated in uncomplicated malaria compared to severe malaria in Indonesian adults and children [10] and may be a novel target of protective antibodies to cerebral malaria.

The selected combination of seven antibody features that could best distinguish between cerebral and uncomplicated malaria included antigen specific antibody engagement with C1q and Fc γ RIIIb responses and IgG2 and IgG4 responses. Recent work from our group has shown that complement deposition leads to antibody mediated lysis of VAR2CSA IE at high concentrations of antibodies (unpublished). However, another recent study found that complement component 1 s (C1s) cleaves PfEMP1 at sites found in interdomain regions, including in IT4VAR13 [46]. Additionally, C1q deposition relies on formation of antibody hexamers and the distribution of PfEMP1 and antibodies on the bead-based multiplex platform are unlikely to accurately represent the surface of the IE [47]. Antibodies to malaria sporozoites that fix complement can inhibit their motility and invasion [48], and complement fixation can enhance antibody mediated phagocytosis [49]. Therefore, the relevance of C1q deposition at the DBL β 3 domain to downstream effects on the IE requires further study. Fc γ RIIIb is highly expressed on neutrophils and can work in concert with Fc γ RIIa to induce ADNP [50] but is not involved in the release of reactive oxygen species [51].

The detection of IgG2 and IgG4 specific antibodies as correlates of protection was unexpected, but one or both antibody subclass responses have been identified as correlates of protection in malaria vaccine studies [52, 53] and IgG4 to CSP was a correlate of naturally acquired protection in Malian children [54]. Antibody responses to recombinant group A and group B ICAM-1 binders are dominated by the cytophilic subclasses, IgG1 and IgG3 [55], and most children we studied had low or

undetectable IgG2 and IgG4. Their selection may reflect greater class switch recombination associated with a more mature antibody response [56] as indicated by their selection in older rather than younger children. Although the specific function of IgG2 and IgG4 targeting PfEMP1 is unclear, they may be useful biomarkers of protective immunity.

ADNP is emerging as a correlate of naturally acquired protection from malaria in pregnancy and children [19, 54] and as an important correlate of vaccine-induced immunity [57–59]. ADNP has been implicated in clearance of VAR2CSA expressing IE [19] and ICAM-1 binding IE [16]. To further assess the role of Fc γ RIIIb binding to antibodies targeting ICAM-1 binding DBL β domains in protection from cerebral malaria, we measured ADNP of two lines of ICAM-1 binding IE. In line with the recombinant protein interactions, we found that ADNP of IE expressing ICAM-1+EPCR binding IE (that contain DBL β 3_Pfd1235w) was elevated in uncomplicated malaria compared to cerebral malaria, in keeping with the published associations between ICAM-1+EPCR binding PfEMP1 types and cerebral malaria [6]. In contrast, ADNP of ICAM-1+CD36 binding IE (that contain DBL β 3_IT4VAR13) was elevated in cerebral malaria. Further, phagocytosis of ICAM-1+EPCR binding IE by THP-1 cells, which lack Fc γ RIIIa or b, was elevated in cerebral malaria. This suggests that children who are protected from cerebral malaria have Fc γ RIIIb binding antibodies that target ICAM-1 binding DBL β and which promote phagocytosis of ICAM-1+EPCR binding IE by neutrophils. The higher levels of phagocytosis of these ICAM-1+EPCR binding IE by THP-1 cells in the CM group were unexpected and warrant further investigation, and future studies will further characterize the relationship between antibodies to recombinant domains and to IE expressing the intact PfEMP1.

Systems serology is based on the idea that “neutralizing” antibody titers alone do not capture the complexity of the immune response. In the context of malaria, systems serology has been applied to characterize functional antibody responses to Rh5 vaccination [60], RTS,S/AS01 vaccination [52], placental malaria [19], and protection from parasitemia and clinical malaria in children [54]. Like those studies, we observed that total IgG may not be an accurate predictor of protection from malaria. This finding has been mirrored in a recent study of immunity to IE in pregnant women, in which functional antibodies that promoted phagocytosis by monocytes or neutrophils were better at differentiating between women who were protected from placental malaria or who were susceptible, compared to total IgG levels towards recombinant

VAR2CSA proteins or the VAR2CSA-expressing placental binding IE [19]. The present study, the placental malaria study [19], and the study of protection from clinical malaria [54] all indicate that a broad range of antibody responses contribute to protection from malaria, findings that have implications for the development of new tools to prevent severe malaria syndromes such as cerebral malaria. Similarly, IgG titer against DBL β domains did not differ in Beninese children with severe or uncomplicated malaria, but opsonic phagocytosis by THP-1 cells induced by a DBL β 3 (group B, IT4VAR13) was elevated in uncomplicated malaria [55]. Our study supports these findings to suggest that rather than the quantity of antibodies targeting PfEMP1, the Fc features and downstream functional activity of antibodies may be more useful correlates of protection.

The interactions between antibodies, recombinant parasite proteins, and recombinant Fc receptors measured by multiplex immunoassay did not correlate with phagocytosis assays using IE (see Additional file 1: Figs. S10 and S11). However, based on the antibody features identified using systems serology, we were able to hypothesize and confirm that ADNP of ICAM-1+EPCR binding IE is associated with protection from cerebral malaria. Therefore, systems serology using recombinant proteins is an effective tool to identify potential mechanisms of protective immunity against IE, but further studies are required to better understand the differences between antibody that binds to a single recombinant protein domain and is detected using isolated Fc receptors, and antibody to a whole PfEMP1 in its native form, measured using a live phagocytic cell.

The pathogenesis of cerebral malaria likely involves multiple factors, including PfEMP1 mediated sequestration of IE in the microvasculature, activation of coagulation pathways, endothelial cell activation, and breakdown of the blood–brain barrier [61]. Previous studies have shown that antibodies targeting DBL β domains can block cytoadhesion of IE and may function to reduce IE sequestration in the brain [21]. Our study adds to current knowledge of protective immunity to cerebral malaria by suggesting that antibodies may facilitate clearance of IE expressing variants of PfEMP1 that are associated with severe malaria, including PfEMP1 with ICAM-1 binding DBL β domains and CIDRy12 domains, via Fc γ RIIIb and C1q mediated pathways such as phagocytosis.

Strengths of the study include well-characterized children with cerebral or uncomplicated malaria who were matched for location, and assessment of a broad array of responses to PfEMP1 antigens, including protein products of genes known to be expressed in severe

or uncomplicated malaria, and PfEMP1 types known to bind to key endothelial receptors. As we have captured a single time point in single infections, interpretation requires caution, and convalescent samples would provide useful insight into the evolution of antibody responses following infection. The dynamics of the antibody response do not necessarily align with those of the disease and the observed responses are likely to be influenced by the timing of sampling. We expect there is variation in the duration of infection prior to presentation to hospital, which we partially accounted for by matching for residency location. However, we were unable to account for the possibility that children with uncomplicated malaria may have progressed to severe malaria without timely treatment. Higher IgG to MSP2 in cerebral malaria compared to uncomplicated malaria may suggest differences in exposure, despite matching of residency location, although there were no differences in IgG responses to other non-PfEMP1 antigens. There is a possibility of differences in exposure over the 3-year sample collection period. Additionally, the antibody responses associated with protection from a single malaria episode do not necessarily represent complete or ongoing protection. Further limitations of this study include the use of recombinant proteins that may not reflect the native protein structure or capture epitopes that span multiple domains, and a relatively small sample size. Stratifying our data by participant age may have limited our power to find PfEMP1 antibody responses that are age dependent. Protein expression system did not appear to bias the likelihood of selection. Domains expressed in both WGCF and *Escherichia coli* systems appeared in the top features, including examples of DBL β domains expressed in both systems. Twenty-eight of the 39 PfEMP1 antigens probed in this study were identified in Papuan adults and children with severe malaria, and it is possible that these domains may be more relevant to manifestations of severe malaria other than cerebral malaria or may be more relevant in Papua than Africa, and even better separation of groups might be obtained with more locally adapted multiplex protein arrays. Due to limited plasma availability, experiments were conducted once. Validation in other sample sets will be important. Expression of PfEMP1 with EPCR binding CIDR α 1 domains has been associated with severe malaria in several studies; however, only one CIDR α 1 domain (CIDR α 1.6) was well recognized in this population and other variants may be more relevant. It is also possible that including multiple examples of some domains may have increased the probability of them appearing in the selected features.

In this exploratory study, we performed a detailed characterization of the domain specific antibody responses in children with cerebral malaria. The systems serology approach may be used in future studies to characterize geographical and age-dependent differences in the antibody response to PfEMP1 variants, as well as temporal associations with protection. Half of PfEMP1 antigens were recognized by less than 25% of children with cerebral or uncomplicated malaria (see Additional file 1: Fig. S3), indicating that children in both clinical groups had many gaps in their antibody repertoire that potentially leave them vulnerable to cerebral malaria in the follow-up period. Longitudinal studies have reported that individuals with antibodies targeting DBL β domains with the DBL β_{motif} have a reduced prospective risk of uncomplicated malaria [9] and high density parasitemia [13] and similar studies to determine the risk of cerebral malaria in the follow-up period would be informative.

Conclusions

This study showed Fc features of antibodies targeting PfEMP1 domains could accurately distinguish between children with cerebral and uncomplicated malaria. Antibodies targeting specific PfEMP1 variants are likely involved in protection against cerebral malaria and PfEMP1 specific antibodies may mediate clearance of IE via C1q and Fc γ RIIIb dependent pathways, such as neutrophil phagocytosis, to protect children from cerebral malaria. Characterizing the antibody response to PfEMP1 may lead to the development of a multivalent PfEMP1-based vaccine or monoclonal antibody cocktail to protect from cerebral malaria by inducing a targeted functional immune response. Future validation of the antibody features identified in this study as correlates of protection may lead to the development of more sensitive prognostic indicators to identify populations and individuals who are susceptible to developing cerebral malaria.

Abbreviations

ADCP	Antibody-dependent cellular phagocytosis
ADNP	Antibody-dependent neutrophil phagocytosis
AMA	Apical membrane antigen
AUROC	Area under the receiver operator curve
BCS	Blantyre coma score
BSA	Bovine serum albumin
CIDR	Cysteine-rich interdomain region
CSP	Circumsporozoite protein
DBL	Duffy binding like
DHE	Dihydroethidium bromide
EBA	Erythrocyte binding antigen
ENLR	Elastic net regularized logistic regression
EPCR	Endothelial protein C receptor
Fc γ R	Fc γ receptor
ICAM-1	Intercellular adhesion molecule-1
IE	Infected erythrocyte
Ig	Immunoglobulin
IQR	Interquartile range
MFI	Median fluorescence intensity

MSP	Merozoite surface protein
PBS	Phosphate buffered saline
PE	Phycoerythrin
<i>P. falciparum</i>	<i>Plasmodium falciparum</i>
PfEMP1	<i>Plasmodium falciparum</i> erythrocyte membrane protein 1
PLSR	Partial Least Squares Regression
SM	Severe Malaria
UM	Uncomplicated Malaria

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12916-024-03604-8>.

Additional file 1: Table 1-2, Figures S1–S11. Table 1–2 - Recombinant proteins used in multiplex assays. Fig S1 - General structure of PfEMP1. Fig S2- IgG responses measured in singleplex compared to multiplex. Fig S3 - Antigen specific IgG seropositivity. Fig S4–S5 - Correlation between age and antibody responses. Fig S6–S7 - ENLR with alpha tuning parameter set to 0.25 and 1. Fig S8–S9- Correlation between features most frequently selected by ENLR. Fig S10–S11 - Correlation between ADNP and ADCP of IE and antibody features targeting related recombinant proteins.

Additional file 2: Box and whisker plots comparing cerebral and uncomplicated malaria for grouped antigens.

Additional file 3: Box and whisker plots comparing cerebral and uncomplicated malaria for all variables.

Acknowledgements

We thank Bruce Wines and Mark Hogarth, Burnet Institute, for the kind provision of Fc dimers. We thank Ricardo Ataide and Jack Richards for the kind provision of the EBA175-RIII-V protein. We thank the staff of the MLW Clinical Research Programme and Blantyre Malaria Project in Malawi for assistance in recruiting and caring for study participants, and the children and their families who donated the samples used in this work.

Authors' contributions

Conceptualization, S.J.R., E.H.A., A.W.C.; investigation, I.S.W., T.D., W.H., A.A.; validation, A.W.C.; formal analysis, I.S.W., S.D.; writing—original draft, I.S.W., S.J.R.; writing—review and editing, E.H.A., S.D., T.D., A.T.R.J., D.H.O., J.S.R., M.F.D., J.A.S., T.E.T., K.B.S., A.W.C.; resources, K.B.S., T.E.T., A.T.R.J., E.T., T.T., J.S.R., M.F.D., D.H.O., W.M., V.H.; supervision, J.A.S., S.J.R., E.H.A.; funding acquisition, S.J.R., E.H.A., A.W.C. All authors read and approved the final manuscript.

Funding

This work was supported by the National Health and Medical Research Council of Australia (NHMRC) through grants GNT1061993 and GNT1092789 to S.J.R. ATRJ was supported by the Lundbeck Foundation (R313-2019–322). JAS and AWC are supported by NHMRC Investigator Awards 1196068 (JAS) and 2008092 (AWC). ISW was supported by a University of Melbourne Research Training Program Scholarship and Rowden White Scholarship.

Availability of data and materials

The data sets generated during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

For plasma samples, written, informed consent was obtained from guardians of all participants. For peripheral blood used for neutrophil isolation, written, informed consent was obtained from all participants. The studies were approved by the College of Medicine Research Ethics Committee, University of Malawi, P11/14/1656, and by the Melbourne Health Human Research Ethics Committee, approval 2013.290.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Medicine, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. ²Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC 3010, Australia. ³Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. ⁴Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. ⁵Centre for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁶Burnet Institute, 85 Commercial Road, Melbourne, VIC 3004, Australia. ⁷Department of Immunology, Monash University, Melbourne, VIC, Australia. ⁸Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan. ⁹Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. ¹⁰Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Japan. ¹¹Academy of Medical Sciences, Malawi University of Science and Technology, Thyolo, Malawi. ¹²Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi. ¹³College of Osteopathic Medicine, Michigan State University, East Lansing, USA.

Received: 28 November 2023 Accepted: 3 September 2024

Published online: 12 September 2024

References

- World malaria report 2023. World Health Organization. 2023. <https://www.who.int/teams/global-malaria-programme/reports>.
- Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. *Nat Med*. 2004;10:143–5.
- Rask TS, Hansen DA, Theander TG, Pedersen AG, Lavstsen T. Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes - divide and conquer. *PLoS Comput Biol*. 2010;6: e1000933.
- Lavstsen T, Gilbert MTP, Willerslev E, Baraka V, Theander TG, Marquard AM, et al. Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. *Proc Natl Acad Sci*. 2012;109:e1791–800.
- Kessler A, Dankwa S, Bernabeu M, Harawa V, Danziger SA, Duffy F, et al. Linking EPCR-binding PfEMP1 to brain swelling in pediatric cerebral malaria. *Cell Host Microbe*. 2017;22:601–614.e5.
- Lennartz F, Adams Y, Bengtsson A, Olsen RW, Turner L, Ndam NT, et al. Structure-guided identification of a family of dual receptor-binding PfEMP1 that is associated with cerebral malaria. *Cell Host Microbe*. 2017;21:403–14.
- Tuikue Ndam N, Moussilou A, Lavstsen T, Kamaliddin C, Jensen ATR, Mama A, et al. Parasites causing cerebral falciparum malaria bind multiple endothelial receptors and express EPCR and ICAM-1-binding PfEMP1. *J Infect Dis*. 2017;215:1918–25.
- Adams Y, Olsen RW, Bengtsson A, Dalgaard N, Zdiourk M, Satpathi S, et al. Plasmodium falciparum erythrocyte membrane protein 1 variants induce cell swelling and disrupt the blood–brain barrier in cerebral malaria. *J Exp Med*. 2021;218: e20201266.
- Kanoi BN, Nagaoka H, Morita M, White MT, Palacpac NMQ, Ntege EH, et al. Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains. *Vaccine*. 2018;36:6826–33.
- Rambhatla JS, Tonkin-hill GQ, Takashima E, Tsuboi T, Noviyanti R, Trianty L, et al. Identifying targets of protective antibodies against severe malaria in Papua, Indonesia, using locally expressed domains. *Infect Immun*. 2022;90: e0043521.
- Travassos MA, Niangaly A, Bailey JA, Ouattara A, Coulibaly D, Lyke KE, et al. Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. *Sci Rep*. 2018;8:6281.
- Obeng-Adjei N, Larremore DB, Turner L, Ongoiba A, Li S, Doumbo S, et al. Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection. *JCI Insight*. 2020;5: e137262.
- Tessema SK, Utama D, Chesnokov O, Hodder AN, Lin CS, Harrison GLA, et al. Antibodies to intercellular adhesion molecule 1-binding Plasmodium falciparum erythrocyte membrane protein 1-DBL β are biomarkers of protective immunity to malaria in a cohort of young children from Papua New Guinea. *Infect Immun*. 2018;86:1–14.
- Tessema SK, Nakajima R, Jasinskas A, Monk SL, Lekieffre L, Lin E, et al. Protective immunity against severe malaria in children is associated with a limited repertoire of antibodies to conserved PfEMP1 variants. *Cell Host Microbe*. 2019;26:579–590.e5.
- Chan JA, Boyle MJ, Moore KA, Reiling L, Lin Z, Hasang W, et al. Antibody targets on the surface of Plasmodium falciparum-infected erythrocytes that are associated with immunity to severe malaria in young children. *J Infect Dis*. 2019;219:819–28.
- Zelter T, Strahilevitz J, Simantov K, Yajuk O, Adams Y, Jensen AR, et al. Neutrophils impose strong immune pressure against PfEMP1 variants implicated in cerebral malaria. *EMBO Rep*. 2022;23: e53641.
- Arora G, Hart GT, Manzella-Lapeira J, Doritchamou JY, Narum DL, Thomas LM, et al. NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity. *Elife*. 2018;7:1–20.
- Arnold KB, Chung AW. Prospects from systems serology research Immunology. 2018;153:279–89.
- Aitken EH, Damelang T, Ortega-Pajares A, Alemu A, Hasang W, Dini S, et al. Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. *Elife*. 2021;10:1–30.
- Tonkin-Hill GQ, Trianty L, Noviyanti R, Nguyen HHT, Sebayang BF, Lampah DA, et al. The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes. *PLoS Biol*. 2018;16: e2004328.
- Olsen RW, Ecklu-Mensah G, Bengtsson A, Ofori MF, Lusingu JP, Castberg FC, et al. Natural and vaccine-induced acquisition of cross-reactive IgG-inhibiting ICAM-1-specific binding of a Plasmodium falciparum PfEMP1 subtype associated specifically with cerebral malaria. *Infect Immun*. 2018;86:1–17.
- Harawa V, Njie M, Kessler A, Choko A, Kumwenda B, Kampondeni S, et al. Brain swelling is independent of peripheral plasma cytokine levels in Malawian children with cerebral malaria. *Malar J*. 2018;17:435.
- Molyneux ME, Taylor TE, Wirimaf JJ, Borgstein J. Clinical features and prognostic indicators in paediatric cerebral malaria a study of 131 comatose Malawian children. *Q J Med*. 1989;71:441–59.
- Olsen RW, Ecklu-Mensah G, Bengtsson A, Ofori MF, Kusi KA, Koram KA, et al. Acquisition of IGG to ICAM-1-binding DBL β domains in the Plasmodium falciparum erythrocyte membrane protein 1 antigen family varies between groups A, B, and C. *Infect Immun*. 2019;87:e00224–e319.
- Bengtsson A, Joergensen L, Rask TS, Olsen RW, Andersen MA, Turner L, et al. A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies. *J Immunol*. 2013;190:240–9.
- Walker IS, Chung AW, Damelang T, Rogerson SJ. Analysis of antibody reactivity to malaria antigens by microsphere-based multiplex immunoassay. In: Hviid L, editor. *Malaria immunology. Methods in molecular biology*. New York: Humana; 2022. p. 309–25.
- Wines BD, Vandervan HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric Fc γ R ectodomains as probes of the Fc receptor function of anti-influenza virus IgG. *J Immunol*. 2016;197:1507–16.
- Jensen JB. In vitro culture of Plasmodium parasites. In: Doolan DL, editor. *Malaria methods and protocols*. Totowa: Humana; 2002. p. 477–88.
- Joergensen L, Bengtsson DC, Bengtsson A, Ronander E, Berger SS, Turner L, et al. Surface co-expression of two different PfEMP1 antigens on single plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1. *PLoS Pathog*. 2010;6: e1001083.
- Lennartz F, Bengtsson A, Olsen RW, Joergensen L, Brown A, Remy L, et al. Mapping the binding site of a cross-reactive Plasmodium falciparum PfEMP1 monoclonal antibody inhibitory of ICAM-1 binding. *J Immunol*. 2015;195:3273–83.
- Ataide R, Hasang W, Wilson DW, Beeson JG, Mwapasa V, Molyneux ME, et al. Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria. *PLoS ONE*. 2010;5: e10807.

32. Kassa MW, Hasang W, Rogerson SJ. Antibody-dependent THP-1 cell-mediated phagocytosis of *Plasmodium falciparum*-infected erythrocytes. In: Hviid L, editor. *Jensen ATR. Malaria immunology. Methods in molecular biology*. New York: Humana; 2022. p. 617–28.
33. Tebo AE, Kremsner PG, Luty AJF. Fcγ receptor-mediated phagocytosis of *Plasmodium falciparum*-infected erythrocytes in vitro. *Clin Exp Immunol*. 2002;130:300–6.
34. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. *J Stat Softw*. 2011;45:1–67.
35. Zou H, Hastie T. Regularization and variable selection via the elastic net. *J R Stat Soc Ser B (Statistical Methodology)*. 2005;67:301–20.
36. Beare NAV, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: a newly established diagnostic sign in severe malaria. *Am J Trop Med Hyg*. 2006;75:790–7.
37. Barry AE, Trieu A, Fowkes FJL, Pablo J, Kalantari-Dehaghi M, Jasinskas A, et al. The stability and complexity of antibody responses to the major surface antigen of *Plasmodium falciparum* are associated with age in a malaria endemic area. *Mol Cell Proteomics*. 2011;10:M111.008326.
38. Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. *Cell Host Microbe*. 2018;24:221–233.e5.
39. Lusingu JPA, Jensen ATR, Vestergaard LS, Minja DT, Dalgaard MB, Gesase S, et al. Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved *Plasmodium falciparum* erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes. *Infect Immun*. 2006;74:2867–75.
40. Kessler A, Campo JJ, Harawa V, Mandala WL, Rogerson SJ, Mowrey WB, et al. Convalescent *Plasmodium falciparum*-specific seroreactivity does not correlate with paediatric malaria severity or *Plasmodium* antigen exposure. *Malar J*. 2018;17:178.
41. Badaut C, Visitdesotrakul P, Chabry A, Bigey P, Torniyigah B, Roman J, et al. IgG acquisition against PfEMP1 PF11_0521 domain cassette DC13, DBLβ3_D4 domain, and peptides located within these constructs in children with cerebral malaria. *Sci Rep*. 2021;11:1–12.
42. Otto TD, Assefa SA, Böhme U, Sanders MJ, Kwiatkowski D, Berriman M, et al. Evolutionary analysis of the most polymorphic gene family in *falciparum* malaria. *Wellcome open Res*. 2019;4:193.
43. Chesnokov O, Merritt J, Tcherniuk SO, Milman N, Oleinikov AV. *Plasmodium falciparum* infected erythrocytes can bind to host receptors integrins αVβ3 and αVβ6 through DBLδ1_D4 domain of PFL2665c PfEMP1 protein. *Sci Rep*. 2018;8:17871.
44. Gillrie MR, Renaux B, Russell-Goldman E, Avril M, Brazier AJ, Mihara K, et al. Thrombin cleavage of *Plasmodium falciparum* erythrocyte membrane protein 1 inhibits cytoadherence. *MBio*. 2016;7:e01120–e1216.
45. Ghumra A, Khunrae P, Ataide R, Raza A, Rogerson SJ, Higgins MK, et al. Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to *Plasmodium falciparum*. *PLoS ONE*. 2011;6: e16414.
46. Azasi Y, Low LM, Just AN, Raghavan SSR, Wang CW, Valenzuela-Leon P, et al. Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting *Plasmodium falciparum* cytoadherence. *Proc Natl Acad Sci USA*. 2021;118: e2104166118.
47. Larsen MD, del Pilar QM, Ditlev SB, Bayarri-Olmos R, Ofori MF, Hviid L, et al. Evasion of classical complement pathway activation on *Plasmodium falciparum*-infected erythrocytes opsonized by PfEMP1-specific IgG. *Front Immunol*. 2019;9:3088.
48. Kurtovic L, Behet MC, Feng G, Reiling L, Chelimo K, Dent AE, et al. Human antibodies activate complement against *Plasmodium falciparum* sporozoites, and are associated with protection against malaria in children. *BMC Med*. 2018;16:61.
49. Opi DH, Kurtovic L, Chan J-A, Horton JL, Feng G, Beeson JG. Multi-functional antibody profiling for malaria vaccine development and evaluation. *Expert Rev Vaccines*. 2021;20:1257–72.
50. Garcia-Senosiani A, Kana IH, Singh S, Das MK, Dziegiel MH, Hertegonne S, et al. Neutrophils dominate in opsonic phagocytosis of *P. falciparum* blood-stage merozoites and protect against febrile malaria. *Commun Biol*. 2021;4:984.
51. Kapelski S, Klockenbring T, Fischer R, Barth S, Fendel R. Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to *Plasmodium falciparum*. *J Leukoc Biol*. 2014;96:1131–42.
52. Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. *Sci Transl Med*. 2020;12:eabb4757.
53. Nielsen CM, Barrett JR, Davis C, Fallon JK, Goh C, Mitchell AR, et al. Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. *JCI insight*. 2023;8:e163859.
54. Nziza N, Tran TM, DeRiso EA, Dolatshahi S, Herman JD, de Lacerda L, et al. Accumulation of neutrophil phagocytic antibody features tracks with naturally acquired immunity against malaria in children. *J Infect Dis*. 2023;228:759–68.
55. Suurbaar J, Moussiliou A, Tahar R, Olsen RW, Adams Y, Dalgaard N, et al. ICAM-1-binding *Plasmodium falciparum* erythrocyte membrane protein 1 variants elicits opsonic-phagocytosis IgG responses in Beninese children. *Sci Rep*. 2022;12:12994.
56. Allen CDC. Features of B cell responses relevant to allergic disease. *J Immunol*. 2022;208:257–66.
57. Kurtovic L, Atre T, Feng G, Wines BD, Chan J-A, Boyle MJ, et al. Multifunctional antibodies are induced by the RTS, S malaria vaccine and associated with protection in a phase 1/2a trial. *J Infect Dis*. 2021;224:1128–38.
58. Feng G, Kurtovic L, Agius PA, Aitken EH, Sacarlal J, Wines BD, et al. Induction, decay, and determinants of functional antibodies following vaccination with the RTS, S malaria vaccine in young children. *BMC Med*. 2022;20:1–18.
59. Das J, Fallon JK, Yu TC, Mitchell A, Suscovich TJ, Linde C, et al. Delayed fractional dosing with RTS, S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and Pf16-specific antibodies. *Med*. 2021;2:1269–1286.e9.
60. Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. *Med*. 2021;2:701–719.e19.
61. Jensen AR, Adams Y, Hviid L. Cerebral *Plasmodium falciparum* malaria: the role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. *Immunol Rev*. 2020;293:230–52.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.